ERBB2 and breast cancer: In this study, 3222 patients with early-stage HER2-positive breast cancer were randomized to receive adjuvant CT with doxorubicin and cyclophosphamide followed by docetaxel (AC-T), the same CT regimen plus 52 weeks of trastuzumab (AC-TH), or docetaxel and carboplatin plus 52 weeks of trastuzumab (TCH).